Reuters Market Eye - Shares in Natco Pharma Ltd
A U.S. Supreme Court justice on Wednesday declined a request from Teva for a stay of an appeals court ruling that would strip the company's $4 billion-a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015.
In July, the U.S. Court of Appeals for the Federal Circuit issued a decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis AG
(Reporting by Abhishek Vishnoi)
